Mysildecard (Sildenafil)

Mysildecard (sildenafil) acts on the phosphodiesterase‑5 pathway to improve vascular smooth‑muscle relaxation in several conditions.

• Erectile dysfunction: enhances the ability to achieve and maintain an erection suitable for sexual activity.
• Pulmonary arterial hypertension: lowers pulmonary arterial pressure and improves exercise capacity.
• Male sexual dysfunction: supports satisfactory sexual performance when other therapies are insufficient.

• Sildenafil selectively inhibits the phosphodiesterase type 5 enzyme, preventing the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP leads to relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature, facilitating increased blood flow and the physiological responses required for erection and reduced pulmonary arterial pressure.

Common side effects are generally mild and transient.

Common Side Effects

• Headache
• Flushing
• Dyspepsia or indigestion
• Nasal congestion
• Visual disturbances (e.g., blue‑tinted vision)
• Back pain or muscle aches

Serious or Rare Side Effects

• Priapism (prolonged erection lasting >4 hours)
• Sudden loss of vision (non‑arteritic anterior ischemic optic neuropathy)
• Sudden hearing loss or tinnitus
• Severe hypotension, especially with nitrates
• Allergic reactions such as rash or angioedema
• Myocardial infarction or stroke in high‑risk patients

Before prescribing Mysildecard, clinicians should evaluate cardiovascular status and concomitant medications.

• Cardiovascular assessment: ensure patient can tolerate sexual activity.
• Nitrate therapy: avoid co‑administration due to risk of severe hypotension.
• Severe renal or hepatic impairment: dose adjustment may be required.
• Hypotension risk: monitor patients on antihypertensives.
• Hypersensitivity: discontinue if allergic reaction occurs.
• Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Sildenafil may interact with several drug classes; careful review is essential.

Major Interactions (Avoid)

• Nitrates (e.g., nitroglycerin): can cause profound hypotension.
• Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect.
• Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase sildenafil exposure.
• Alpha‑blockers (certain agents): may lead to marked blood pressure drops.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Other antihypertensives: monitor blood pressure for additive effects.
• Protease inhibitors (e.g., ritonavir): may increase plasma levels.
• Certain antifungals (e.g., fluconazole): may modestly raise exposure.